TORONTO, ON, Oct. 13, 2022 (GLOBE NEWSWIRE) — marble uses its flagship legal product, Medchart, to issue claimant authorization to law firms representing patients in Mallinckrodt Pharmaceuticals’ opioid lawsuit. Powered by Marble’s APIs, Medchart enables mass tort and personal injury law firms to easily, securely, and affordably access and share patient-authorized digital health information for patient claims.
Medchart played a leading role in qualifying claimants by reviewing medical records for Purdue Pharma’s litigation. This experience helped refine the offering further into an end-to-end legal onboarding solution. With Medchart applicant onboarding (intake), companies can efficiently authenticate customers, assist in creating registration questions for proof of claim submissions, and assist applicants in creating commitment forms for the Mallinckrodt Mass Tort.
Profitability is also a key value driver of the technology. Law firms can significantly streamline their processes by reducing the time it takes to prepare medical data requests, obtain client approvals, and review records that are critical to the success of a case. By enabling law firms to quickly process accurate medical information, Medchart helps increase the firm’s bottom line while reducing victims’ time to justice.
Focus on Mallinckrodt
Between 2006 and 2014, Mallinckrodt Pharmaceuticals accounted for 27 percent of the opioid market compared to 18 percent for Purdue Pharma based on the potency of the pills they produced, according to one analysis from the Washington Post. Currently, the Purdue Pharma case is in final settlement proceedings with a number of US states with unresolved financial claims against the company.
“With the Purdue trial technically on hold, law firms are turning their attention to Mallinckrodt,” said Damon Spiceland, Marble’s head of mass tort operations. “Given the unique needs of each case, we can create new…
